Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration
marketwatch.com
news
2022-06-02 11:50:23

Regeneron Pharmaceuticals Inc. REGN, -0.88% announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s SNY, -0.08% stake in the Regeneron-Sanofi collaboration on cancer treatment Libtayo. Under terms of the deal, Regeneron will make an upfront payment of $900 million, and Sanofi will be entitled to a $100 million regulatory milestone and up to $100 million in sales-related milestone payments. Sanofi will also receive an 11% royalty on global Libtayo sales.
